Business Wire: Promedior Announces Completion of Patient Enrollment Milestones in Phase 2 Clinical Studies of PRM-151 in Both Idiopathic Pulmonary Fibrosis and Myelofibrosis The idiopathic pulmonary fibrosis (IPF) trial completed the enrollment of 117 patients while the myelofibrosis trial completed enrollment of 84 patients. Promedior plans to present the results of ... Promedior Announces Completion of Patient Enrollment Milestones in Phase 2 Clinical Studies of PRM-151 in Both Idiopathic Pulmonary Fibrosis and Myelofibrosis EurekAlert!: Pediatric bone marrow myelofibrosis: A heterogeneous “entity” requiring refined classification to guide therapy Pediatric bone marrow myelofibrosis: A heterogeneous “entity” requiring refined classification to guide therapy Understanding Myelofibrosis:Myelofibrosis is a rare type of blood cancer that begins in the bone marrow, the spongy tissue responsible for producing blood cells.
In this condition:-The bone marrow ... Cure Today: Educated Patient® MPN Summit Differentiating an Essential Thrombocythemia Diagnosis Presentation: When being diagnosed with a myeloproliferative neoplasm (MPN), it is crucial — though oftentimes difficult — to come to the proper diagnosis, especially when differentiating between two subtypes of ...
